Marketdash
Back to Stock Market News

Ultragenyx Pharmaceutical Plunges 42% on Failed Drug Trial: Monday's Biggest Movers

MarketDash Editorial Team
2 hours ago
Ultragenyx Pharmaceutical shares crashed after disappointing Phase 3 trial results for a drug treating brittle bone disease. Meanwhile, markets saw dramatic swings across biotech, precious metals, and tech sectors with several stocks posting triple-digit moves.

When pharmaceutical trial results miss their mark, the market doesn't just register disappointment. It delivers brutal, immediate judgment. That's exactly what happened Monday to Ultragenyx Pharmaceutical Inc. (RARE), which saw its shares crater 42% to $19.84 after revealing clinical trial results that, well, weren't what anyone hoped for.

The biotech company, along with its partner Mereo BioPharma, announced results from the Phase 3 Orbit and Cosmic studies testing setrusumab (UX143) for Osteogenesis Imperfecta. If you're not familiar, Osteogenesis Imperfecta is a group of genetic disorders that affect bone metabolism. The collagen mutations involved make bones extraordinarily brittle, leading to high fracture rates. It's a serious condition that desperately needs effective treatments, which makes the trial failure all the more disappointing.

The damage wasn't limited to Ultragenyx. Mereo BioPharma Group plc (MREO) had an even worse day, plummeting 90% to $0.23. The company disclosed that its Phase 3 ORBIT and COSMIC studies for setrusumab failed to achieve statistical significance against the primary endpoints. Specifically, the drug didn't show a meaningful reduction in annualized clinical fracture rate compared to either placebo or bisphosphonates. That's the kind of news that can essentially vaporize a biotech stock's value overnight.

The Day's Biggest Winners

While Ultragenyx faced headwinds, other parts of the market saw remarkable strength. Republic Power Group Ltd (RPGL) absolutely exploded, surging 163% to $0.69 in what amounted to the session's most impressive percentage gain.

Brand Engagement Network Inc (BNAI) jumped 84.3% to $2.21 after announcing it entered into a Vendor Services Project Agreement with a global advertising and communications agency. That's the kind of corporate partnership news that can light a fire under a small-cap stock.

Globavend Holdings Ltd (GVH) gained 58.5% to $4.12, while CCSC Technology International Hldngs Ltd (CCTG) rose 57.3% to $0.20. 3 E Network Technology Group Ltd (MASK) climbed 34.8% to $0.25.

Corporate actions drove some notable moves. Eightco Holdings Inc (ORBS) shares jumped 29.1% to $2.15 after announcing a share buyback program for up to $125 million. Buyback announcements tend to signal management confidence and provide technical support for the stock.

Greenwich Lifesciences Inc (GLSI) gained 25.7% to $26.00 following news that the company extended the lock-up period to September 30, 2026. Lock-up extensions can reduce near-term selling pressure, which investors clearly appreciated.

TROOPS Inc (TROO) surged 23.3% to $2.38, Fitell Corp (FTEL) gained 21.2% to $0.88, and TryHard Holdings Ltd (THH) rose 19.2% to $20.19.

Palisade Bio Inc (PALI) surged 18.6% to $2.55 after Piper Sandler analyst Yasmeen Rahimi initiated coverage with an Overweight rating and announced a price target of $25. That's nearly a 10x upside target from current levels, the kind of bullish call that gets investors' attention.

Regencell Bioscience Holdings Ltd (RGC) gained 16.3% to $24.60, while Praxis Precision Medicines Inc (PRAX) surged 13% to $304.00 after the FDA granted the company Breakthrough Therapy Designation for ulixacaltamide. That FDA designation is a big deal, it's reserved for drugs that show substantial improvement over existing treatments for serious conditions.

Zura Bio Ltd (ZURA) gained 13% to $5.26, and DigitalBridge Group Inc (DBRG) rose 9.9% to $15.30 after announcing it will be acquired by SoftBank Group for a total enterprise value of approximately $4.0 billion. Acquisition announcements usually provide a clear floor for the stock price.

Precigen Inc (PGEN) gained 8.6% to $4.52, while Autolus Therapeutics PLC (AUTL) jumped 7.8% to $1.80. Needham analyst Gil Blum maintained Autolus Therapeutics with a Buy and raised the price target from $10 to $11.

LightPath Technologies Inc (LPTH) rounded out the gainers, climbing 6.6% to $9.62.

The Downside Movers

Beyond the Ultragenyx and Mereo BioPharma debacle, several other stocks faced significant selling pressure.

X3 Holdings Co Ltd (XTKG) fell 42.1% to $0.080, while ECD Automotive Design Inc (ECDA) dropped 38.3% to $0.71. CID HoldCo Inc (DAIC) fell 34.6% to $0.41.

Carbon Revolution PLC (CREV) dipped 27.8% to $1.82, and Northann Corp (NCL) fell 26.5% to $0.23. SMX (Security Matters) PLC (SMX) also dropped 26.5% to $85.60.

Inovio Pharmaceuticals Inc (INO) fell 22.3% to $1.78 after the U.S. Food and Drug Administration accepted the company's Biologics License Application (BLA) for INO-3107 but raised concerns tied to the accelerated approval pathway. That's a mixed bag, acceptance sounds good, but concerns about the approval pathway introduce uncertainty that markets hate.

374Water Inc (SCWO) fell 19.6% to $1.90. The company named Charles Weiser to its Board of Directors, but apparently that news didn't inspire much enthusiasm.

Precious metals stocks took it on the chin as commodities retreated from recent strength. Hycroft Mining Holding Corporation (HYMC) fell 14% to $21.61 as silver pulled back after reaching an all-time high. Americas Gold and Silver Corporation (USAS) similarly dropped 11% to $5.48 on the same precious metals weakness.

Coincheck Group NV (CNCK) fell 11.5% to $3.08, and CapsoVision Inc (CV) declined 11.2% to $11.55.

Uxin Ltd (UXIN) fell 10.8% to $3.41, despite recently reporting a sizable equity raise alongside solid gains in revenue, vehicle sales, and key profitability metrics during its latest quarter. Sometimes even good operational news can't overcome broader market sentiment or concerns about dilution from equity raises.

Monday's session demonstrated the market's capacity for extreme reactions, particularly in biotech where binary events like clinical trial results can make or break a company's prospects. When you're betting on drug development, the outcomes are rarely subtle. They're either breakthrough moments that send stocks soaring, or disappointing failures that crater valuations. Today, Ultragenyx and Mereo learned that lesson the hard way.

Back to Stock Market News

Ultragenyx Pharmaceutical Plunges 42% on Failed Drug Trial: Monday's Biggest Movers

MarketDash Editorial Team
2 hours ago
Ultragenyx Pharmaceutical shares crashed after disappointing Phase 3 trial results for a drug treating brittle bone disease. Meanwhile, markets saw dramatic swings across biotech, precious metals, and tech sectors with several stocks posting triple-digit moves.

When pharmaceutical trial results miss their mark, the market doesn't just register disappointment. It delivers brutal, immediate judgment. That's exactly what happened Monday to Ultragenyx Pharmaceutical Inc. (RARE), which saw its shares crater 42% to $19.84 after revealing clinical trial results that, well, weren't what anyone hoped for.

The biotech company, along with its partner Mereo BioPharma, announced results from the Phase 3 Orbit and Cosmic studies testing setrusumab (UX143) for Osteogenesis Imperfecta. If you're not familiar, Osteogenesis Imperfecta is a group of genetic disorders that affect bone metabolism. The collagen mutations involved make bones extraordinarily brittle, leading to high fracture rates. It's a serious condition that desperately needs effective treatments, which makes the trial failure all the more disappointing.

The damage wasn't limited to Ultragenyx. Mereo BioPharma Group plc (MREO) had an even worse day, plummeting 90% to $0.23. The company disclosed that its Phase 3 ORBIT and COSMIC studies for setrusumab failed to achieve statistical significance against the primary endpoints. Specifically, the drug didn't show a meaningful reduction in annualized clinical fracture rate compared to either placebo or bisphosphonates. That's the kind of news that can essentially vaporize a biotech stock's value overnight.

The Day's Biggest Winners

While Ultragenyx faced headwinds, other parts of the market saw remarkable strength. Republic Power Group Ltd (RPGL) absolutely exploded, surging 163% to $0.69 in what amounted to the session's most impressive percentage gain.

Brand Engagement Network Inc (BNAI) jumped 84.3% to $2.21 after announcing it entered into a Vendor Services Project Agreement with a global advertising and communications agency. That's the kind of corporate partnership news that can light a fire under a small-cap stock.

Globavend Holdings Ltd (GVH) gained 58.5% to $4.12, while CCSC Technology International Hldngs Ltd (CCTG) rose 57.3% to $0.20. 3 E Network Technology Group Ltd (MASK) climbed 34.8% to $0.25.

Corporate actions drove some notable moves. Eightco Holdings Inc (ORBS) shares jumped 29.1% to $2.15 after announcing a share buyback program for up to $125 million. Buyback announcements tend to signal management confidence and provide technical support for the stock.

Greenwich Lifesciences Inc (GLSI) gained 25.7% to $26.00 following news that the company extended the lock-up period to September 30, 2026. Lock-up extensions can reduce near-term selling pressure, which investors clearly appreciated.

TROOPS Inc (TROO) surged 23.3% to $2.38, Fitell Corp (FTEL) gained 21.2% to $0.88, and TryHard Holdings Ltd (THH) rose 19.2% to $20.19.

Palisade Bio Inc (PALI) surged 18.6% to $2.55 after Piper Sandler analyst Yasmeen Rahimi initiated coverage with an Overweight rating and announced a price target of $25. That's nearly a 10x upside target from current levels, the kind of bullish call that gets investors' attention.

Regencell Bioscience Holdings Ltd (RGC) gained 16.3% to $24.60, while Praxis Precision Medicines Inc (PRAX) surged 13% to $304.00 after the FDA granted the company Breakthrough Therapy Designation for ulixacaltamide. That FDA designation is a big deal, it's reserved for drugs that show substantial improvement over existing treatments for serious conditions.

Zura Bio Ltd (ZURA) gained 13% to $5.26, and DigitalBridge Group Inc (DBRG) rose 9.9% to $15.30 after announcing it will be acquired by SoftBank Group for a total enterprise value of approximately $4.0 billion. Acquisition announcements usually provide a clear floor for the stock price.

Precigen Inc (PGEN) gained 8.6% to $4.52, while Autolus Therapeutics PLC (AUTL) jumped 7.8% to $1.80. Needham analyst Gil Blum maintained Autolus Therapeutics with a Buy and raised the price target from $10 to $11.

LightPath Technologies Inc (LPTH) rounded out the gainers, climbing 6.6% to $9.62.

The Downside Movers

Beyond the Ultragenyx and Mereo BioPharma debacle, several other stocks faced significant selling pressure.

X3 Holdings Co Ltd (XTKG) fell 42.1% to $0.080, while ECD Automotive Design Inc (ECDA) dropped 38.3% to $0.71. CID HoldCo Inc (DAIC) fell 34.6% to $0.41.

Carbon Revolution PLC (CREV) dipped 27.8% to $1.82, and Northann Corp (NCL) fell 26.5% to $0.23. SMX (Security Matters) PLC (SMX) also dropped 26.5% to $85.60.

Inovio Pharmaceuticals Inc (INO) fell 22.3% to $1.78 after the U.S. Food and Drug Administration accepted the company's Biologics License Application (BLA) for INO-3107 but raised concerns tied to the accelerated approval pathway. That's a mixed bag, acceptance sounds good, but concerns about the approval pathway introduce uncertainty that markets hate.

374Water Inc (SCWO) fell 19.6% to $1.90. The company named Charles Weiser to its Board of Directors, but apparently that news didn't inspire much enthusiasm.

Precious metals stocks took it on the chin as commodities retreated from recent strength. Hycroft Mining Holding Corporation (HYMC) fell 14% to $21.61 as silver pulled back after reaching an all-time high. Americas Gold and Silver Corporation (USAS) similarly dropped 11% to $5.48 on the same precious metals weakness.

Coincheck Group NV (CNCK) fell 11.5% to $3.08, and CapsoVision Inc (CV) declined 11.2% to $11.55.

Uxin Ltd (UXIN) fell 10.8% to $3.41, despite recently reporting a sizable equity raise alongside solid gains in revenue, vehicle sales, and key profitability metrics during its latest quarter. Sometimes even good operational news can't overcome broader market sentiment or concerns about dilution from equity raises.

Monday's session demonstrated the market's capacity for extreme reactions, particularly in biotech where binary events like clinical trial results can make or break a company's prospects. When you're betting on drug development, the outcomes are rarely subtle. They're either breakthrough moments that send stocks soaring, or disappointing failures that crater valuations. Today, Ultragenyx and Mereo learned that lesson the hard way.